Wall Street equity research analysts tracking Nkarta Inc. (NKTX) maintain an average twelve-month consensus price target that sits significantly higher than its current trading range, reflecting optimistic expectations for its engineered cell therapy pipeline. Depending on the specific institutional research desk, target projections hover around elevated double-digit figures, representing substantial potential percentage upside from its baseline share price. Analysts base these forecasts on clinical milestone progress in autoimmune and oncology applications, though early-stage biotech valuations remain highly sensitive to research updates.